Advancing novel therapeutic solutions
for life-threatening infections.
Our Focus
Amplyx Pharmaceuticals is developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune compromised patients.
Patients undergoing chemotherapy and other immunosuppressive treatments end up with compromised immune systems. This makes them susceptible to a new disease—invasive fungal infections. By treating their underlying condition, patients are now open to a new life-threatening disease.
Yet, existing therapies for invasive fungal infections are extremely limited on many fronts—they’re difficult to administer, can have toxic side effects and are ineffective against more potent fungi which have developed resistance.
Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive fungal infections planned for initiation in 2018.
About Us
Amplyx was founded on a mission to develop a new class of antifungal medicine that would overcome the severe limitations of today’s therapy options.
Amplyx has a proven management team and strong financial position, having raised a total of $118.5 million in venture capital and received more than $10 million in grants from the National Institutes of Health. Amplyx initiated clinical trials in 2016 for its novel drug candidate APX001.
The company is based in San Diego, California.
“There hasn’t been a new class of antifungal drug approved since 2001, and many existing antifungal agents are difficult to use, poorly tolerated or ineffective due to the rise of drug-resistant strains.”
— Mike Grey,
Executive Chairman, Amplyx Pharmaceuticals
Management
Ciara Kennedy, Ph.D.
President and CEO
Mike Hodges, M.D.
Chief Medical Officer
Karen Joy Shaw, Ph.D.
Chief Scientific Officer
Alan Fuhrman
Chief Financial Officer
Paul Bien
Vice President, Program Management & Operations
Susan Dubé
Vice President, Business Development & Administration
Elizabeth Gordon, Ph.D.
Vice President, Regulatory Affairs
Pamela Wedel
Vice President, Clinical Operations
News
Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference
If you’re a member of the media and would like to reach Amplyx, please contact:
Heidi Chokeir, Ph.D.
Senior Vice President, Canale Communications
(619) 849-5377
heidi@canalecomm.com
Careers
Amplyx is driven by a mission to develop the best treatment for patients with life-threatening fungal infections. Our growing team brings a long history of drug development experience, effective company leadership and spirited collaboration. As we expand, we continue to welcome passionate and talented individuals who share our desire to create new possibilities in medicine.
Amplyx offers a competitive compensation package and a rewarding work environment that fosters innovation. We invite you to explore our career opportunities. If you don’t find a perfect job match on our website, but think Amplyx may be the right place for your, please submit your resume to careers@amplyx.com.